Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AHB-137 with Single Ascending Doses and Multiple Doses in Healthy Volunteers and Initial Efficacy in Chronic Hepatitis B Patients

NCT05717686 is registered in ClinicalTrials.gov with AusperBio Therapeutics Inc. as lead sponsor.

NCT NCT05717686
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05717686 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AHB-137 with Single Ascending Doses and Multiple Doses in Healthy Volunteers and Initial Efficacy in Chronic Hepatitis B Patients
Lead sponsor
AusperBio Therapeutics Inc.
Phase
Phase 1
Overall status
Completed
Start date
February 28, 2023
Completion date
January 7, 2025
Enrollment
64 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b